Vincenzino Salimbeni, Canio Martinelli, Lavinia Porto, M. Donne, Angela Alibrandi, Francesco Di Pierro, Flaviana Cau, R. Granese, Vito Iannone, Liliana Marchetta, Alfredo Ercoli, Combining Ahcc, L. Crispatus
: Human papillomavirus (HPV), especially high-risk types like HPV 16 and 18, can progress from low-grade lesions (LSIL) to cancer. While HR-HPV and LSIL often regress naturally, some cases may advance to malignancy. Current treatments vary in efficacy and can have adverse effects. Emerging research on Lactobacillus Crispatus M247 and Active Hexose Correlated Compound (AHCC) shows potential for enhancing HPV clearance and LSIL regression with minimal side effects. However, the precise impact of these treatments remains under study
{"title":"A prospective observational study to evaluate impact of oral supplementation with AHCC and Lactobacillus Crispatus M247 on HPV clearance and low-grade squamous intraepithelial lesion regression","authors":"Vincenzino Salimbeni, Canio Martinelli, Lavinia Porto, M. Donne, Angela Alibrandi, Francesco Di Pierro, Flaviana Cau, R. Granese, Vito Iannone, Liliana Marchetta, Alfredo Ercoli, Combining Ahcc, L. Crispatus","doi":"10.48286/aro.2024.83","DOIUrl":"https://doi.org/10.48286/aro.2024.83","url":null,"abstract":": Human papillomavirus (HPV), especially high-risk types like HPV 16 and 18, can progress from low-grade lesions (LSIL) to cancer. While HR-HPV and LSIL often regress naturally, some cases may advance to malignancy. Current treatments vary in efficacy and can have adverse effects. Emerging research on Lactobacillus Crispatus M247 and Active Hexose Correlated Compound (AHCC) shows potential for enhancing HPV clearance and LSIL regression with minimal side effects. However, the precise impact of these treatments remains under study","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"13 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140404659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
. Impact statement: Dietary interventions have the potential to impact life expectancy and prevent age-related diseases like tumors and neurodegenerative disorders. However, the applicability of calorie restriction and fasting interventions from mouse models to human populations remains controversial and inconclusive. In this review, we examine the potential obstacles that may arise when attempting to apply dietary interventions from mouse models to human populations
{"title":"Calorie restriction and periodic fasting from rodent to human: lost in translation?","authors":"T. Esposito, S. Cortellino","doi":"10.48286/aro.2024.80","DOIUrl":"https://doi.org/10.48286/aro.2024.80","url":null,"abstract":". Impact statement: Dietary interventions have the potential to impact life expectancy and prevent age-related diseases like tumors and neurodegenerative disorders. However, the applicability of calorie restriction and fasting interventions from mouse models to human populations remains controversial and inconclusive. In this review, we examine the potential obstacles that may arise when attempting to apply dietary interventions from mouse models to human populations","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"201 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140403413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. D. Luca, Pasquale Vitale, A. Galvano, Gerardo Rosati, Ilaria Di, Antonino Grassedonia, S. Cordio, Giuseppe Lo Re, R. Addeo, Giuseppe Cicero
: The use of Aflibercept plus Folfiri represents the second-line chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with Oxaliplatin. The outbreak of COVID-19 upset the standardized procedure of routinary access to the hospital with a lot of difficulty in administering chemotherapy. For this reason, we conducted this retrospective study on 78 enrolled patients who were diagnosed with mCRC, through the pandemic period. Primary endpoints were quality of life (QoL), progression-free survival (PFS) and overall response rate (ORR) in two patient groups treated before and after the onset of COVID-19, group A and group B, respectively. Secondary endpoints were tolerability profile, prognostic factors and carcinoembryonic antigen (CEA) reduction. The median age in all patients was 58 years old, and the median PFS was 6.2 months (95% CI: 5.1-7.2). A significant correlation was observed between decreased CEA levels and PFS with a P value of 0.63 (P = 0.009), which led to consequent improvement of QoL. The treatment was well tolerated, with good disease control and a manageable toxicity profile. Our survival analysis shows a non-significant difference in PFS in the two groups of patients treated before and after COVID-19 (6.1 versus 6.2 months). Furthermore, our analysis suggests left-side tumor site and wild-type RAS/BRAF status as potential prognostic factors for PFS and ORR. The results showed therapeutic benefits of AFL plus Folfiri as second-line therapy in mCRC patients previously treated with Oxaliplatin. The use of AFL plus Folfiri showed efficacy and safety, although the COVID-19 pandemic has affected the management of patients’ care.
{"title":"Aflibercept plus FOLFIRI as second-line therapy in metastatic colorectal cancer (mCRC) during pandemic COVID-19: a real-world experience","authors":"R. D. Luca, Pasquale Vitale, A. Galvano, Gerardo Rosati, Ilaria Di, Antonino Grassedonia, S. Cordio, Giuseppe Lo Re, R. Addeo, Giuseppe Cicero","doi":"10.48286/aro.2024.82","DOIUrl":"https://doi.org/10.48286/aro.2024.82","url":null,"abstract":": The use of Aflibercept plus Folfiri represents the second-line chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with Oxaliplatin. The outbreak of COVID-19 upset the standardized procedure of routinary access to the hospital with a lot of difficulty in administering chemotherapy. For this reason, we conducted this retrospective study on 78 enrolled patients who were diagnosed with mCRC, through the pandemic period. Primary endpoints were quality of life (QoL), progression-free survival (PFS) and overall response rate (ORR) in two patient groups treated before and after the onset of COVID-19, group A and group B, respectively. Secondary endpoints were tolerability profile, prognostic factors and carcinoembryonic antigen (CEA) reduction. The median age in all patients was 58 years old, and the median PFS was 6.2 months (95% CI: 5.1-7.2). A significant correlation was observed between decreased CEA levels and PFS with a P value of 0.63 (P = 0.009), which led to consequent improvement of QoL. The treatment was well tolerated, with good disease control and a manageable toxicity profile. Our survival analysis shows a non-significant difference in PFS in the two groups of patients treated before and after COVID-19 (6.1 versus 6.2 months). Furthermore, our analysis suggests left-side tumor site and wild-type RAS/BRAF status as potential prognostic factors for PFS and ORR. The results showed therapeutic benefits of AFL plus Folfiri as second-line therapy in mCRC patients previously treated with Oxaliplatin. The use of AFL plus Folfiri showed efficacy and safety, although the COVID-19 pandemic has affected the management of patients’ care.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"44 S9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140403510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Nerini, S. Burk, E. Andretta, A. Chirico, A. Giordano
: Pediatric patients undergoing cancer treatments often experience excessive pain and anxiety during medical procedures, especially those involving the insertion of needles. These feelings are usually associated with dangerous consequences such as attempts to escape and the avoidance of health care. Therefore, it is essential to improve the management of discomfort and fear to ensure appropriate care for the patients. In recent years, many studies and numerous randomized trials have been focusing on the effects of virtual reality (VR) during distressing procedures and rehabilitation sessions, and it has been reported that VR is a successful form of distraction from both pain and anxiety. This innovative form of non-pharmacological analgesic therapy has also been used together with opioids (standard care), such as morphine, while performing unpleasant therapies, successfully reducing the feelings of distress and fear compared to the patients treated with the standard medications. This manuscript aims to analyze the most recent literature in VR for the management of pain and anxiety during cancer-related treatments in pediatric patients. The use of VR during medical procedures offers patients relaxing and pleasant scenarios. VR represents a promising strategy to alleviate the suffering and stress of pediatric patients, ensuring better patient management.
{"title":"The effects of virtual reality on pain and anxiety in pediatric oncology patients","authors":"C. Nerini, S. Burk, E. Andretta, A. Chirico, A. Giordano","doi":"10.48286/aro.2024.81","DOIUrl":"https://doi.org/10.48286/aro.2024.81","url":null,"abstract":": Pediatric patients undergoing cancer treatments often experience excessive pain and anxiety during medical procedures, especially those involving the insertion of needles. These feelings are usually associated with dangerous consequences such as attempts to escape and the avoidance of health care. Therefore, it is essential to improve the management of discomfort and fear to ensure appropriate care for the patients. In recent years, many studies and numerous randomized trials have been focusing on the effects of virtual reality (VR) during distressing procedures and rehabilitation sessions, and it has been reported that VR is a successful form of distraction from both pain and anxiety. This innovative form of non-pharmacological analgesic therapy has also been used together with opioids (standard care), such as morphine, while performing unpleasant therapies, successfully reducing the feelings of distress and fear compared to the patients treated with the standard medications. This manuscript aims to analyze the most recent literature in VR for the management of pain and anxiety during cancer-related treatments in pediatric patients. The use of VR during medical procedures offers patients relaxing and pleasant scenarios. VR represents a promising strategy to alleviate the suffering and stress of pediatric patients, ensuring better patient management.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"6 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140403945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Mangone, I. Bisceglia, C. Storchi, F. Morabito, M. Pagano, A. Neri, A. Romanelli
: This study aims to describe the incidence of malignant mesothelioma (MM) in the period 1996-2022 and report the related exposure to asbestos. The study includes all cases of MM with a certain or a probable diagnosis (with microscopic confirmation) and possible cases (without microscopic confirmation) collected by the Regional Mesothelioma Registry (ReM) which represents one of the 21 CORs (Regional Operational Centers) in Italy. For each case, information on age, sex, tumor site, morphology, date of diagnosis, follow-up, and province of residence was collected. Data on previous occupational and non-occupational exposure to asbestos, by type of sector and activity, was also collected through an analytical questionnaire, administered to the patient or his closest relatives. Between 1996 and 2022 were registered, 3,357 cases of MM classified as certain (2,870 cases, 85.5%), probable (174 cases, 5.2%), and possible cases (313 cases, 9.2%). The greatest number of cases were recorded for the pleura (3,081) and the peritoneum (245). The province of Bologna (741 cases), Reggio Emilia (508 cases), Parma (390 cases), and Modena (370 cases) recorded the highest number of cases, most of them were registered at age 75+ (1,575 cases). Concerning exposure, 70.5% were defined as professional, 5.9% familiar, 2.2% as environmental, and 1.4% as extra professional. The majority of males had occupational exposure (83.3%) in comparison with 34.3% of women, who showed also family exposure in 20.3% of cases. Bologna confirms the primacy for professional and environmental exposure cases, Reggio Emilia for familiar, and Parma and Bologna for extra-professional exposure.
{"title":"INCIDENCE AND ASBESTOS EXPOSURE OF MALIGNANT MESOTHELIOMA IN THE NORTH ITALIAN REGION","authors":"L. Mangone, I. Bisceglia, C. Storchi, F. Morabito, M. Pagano, A. Neri, A. Romanelli","doi":"10.48286/aro.2023.72","DOIUrl":"https://doi.org/10.48286/aro.2023.72","url":null,"abstract":": This study aims to describe the incidence of malignant mesothelioma (MM) in the period 1996-2022 and report the related exposure to asbestos. The study includes all cases of MM with a certain or a probable diagnosis (with microscopic confirmation) and possible cases (without microscopic confirmation) collected by the Regional Mesothelioma Registry (ReM) which represents one of the 21 CORs (Regional Operational Centers) in Italy. For each case, information on age, sex, tumor site, morphology, date of diagnosis, follow-up, and province of residence was collected. Data on previous occupational and non-occupational exposure to asbestos, by type of sector and activity, was also collected through an analytical questionnaire, administered to the patient or his closest relatives. Between 1996 and 2022 were registered, 3,357 cases of MM classified as certain (2,870 cases, 85.5%), probable (174 cases, 5.2%), and possible cases (313 cases, 9.2%). The greatest number of cases were recorded for the pleura (3,081) and the peritoneum (245). The province of Bologna (741 cases), Reggio Emilia (508 cases), Parma (390 cases), and Modena (370 cases) recorded the highest number of cases, most of them were registered at age 75+ (1,575 cases). Concerning exposure, 70.5% were defined as professional, 5.9% familiar, 2.2% as environmental, and 1.4% as extra professional. The majority of males had occupational exposure (83.3%) in comparison with 34.3% of women, who showed also family exposure in 20.3% of cases. Bologna confirms the primacy for professional and environmental exposure cases, Reggio Emilia for familiar, and Parma and Bologna for extra-professional exposure.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
1 Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta 2 Department of Breast Surgery, Dr. Shterev Hospital, Sofia, Bulgaria 3 Research Institute, Medical University Pleven, Pleven, Bulgaria 4 Bulgarian Breast and Gynecological Cancer Association, Sofia, Bulgaria * Correspondence to: jean.calleja-agius@um.edu.mt, https://orcid.org/0000-0001-6369-0297. Jean Calleja-Agius 1, *, Mariela Vasileva-Slaveva 2, 3, 4 ‘OUR BATTLE FOR BETTER HEALTHCARE IS ETERNAL’. REPORT FROM THE GYNOCARE CONFERENCE IN SOFIA, BULGARIA (2ND-3RD JULY 2023) Annals of Research in Oncology Vol. 3(3), 135-139, 2023
{"title":"‘OUR BATTLE FOR BETTER HEALTHCARE IS ETERNAL’. REPORT FROM THE GYNOCARE CONFERENCE IN SOFIA, BULGARIA (2ND-3RD JULY 2023)","authors":"J. Calleja Agius, M. Vasileva Slaveva","doi":"10.48286/aro.2023.74","DOIUrl":"https://doi.org/10.48286/aro.2023.74","url":null,"abstract":"1 Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta 2 Department of Breast Surgery, Dr. Shterev Hospital, Sofia, Bulgaria 3 Research Institute, Medical University Pleven, Pleven, Bulgaria 4 Bulgarian Breast and Gynecological Cancer Association, Sofia, Bulgaria * Correspondence to: jean.calleja-agius@um.edu.mt, https://orcid.org/0000-0001-6369-0297. Jean Calleja-Agius 1, *, Mariela Vasileva-Slaveva 2, 3, 4 ‘OUR BATTLE FOR BETTER HEALTHCARE IS ETERNAL’. REPORT FROM THE GYNOCARE CONFERENCE IN SOFIA, BULGARIA (2ND-3RD JULY 2023) Annals of Research in Oncology Vol. 3(3), 135-139, 2023","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"IN SEARCH OF THE LOST RIGHTS","authors":"G. Beretta","doi":"10.48286/aro.2023.70","DOIUrl":"https://doi.org/10.48286/aro.2023.70","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"372 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
1 Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta 2 Department of Breast Surgery, Dr. Shterev Hospital, Sofia, Bulgaria 3 Research Institute, Medical University Pleven, Pleven, Bulgaria 4 Bulgarian Breast and Gynecological Cancer Association, Sofia, Bulgaria * Correspondence to: jean.calleja-agius@um.edu.mt, https://orcid.org/0000-0001-6369-0297. Jean Calleja-Agius 1, *, Mariela Vasileva-Slaveva 2, 3, 4 ‘THEY ARE RARE, BUT THEY ARE THERE’. REPORT FROM THE GYNOCARE TRAINING SCHOOL IN SOFIA, BULGARIA (29TH JUNE-1ST JULY 2023) Annals of Research in Oncology Vol. 3(3), 132-134, 2023
{"title":"‘THEY ARE RARE, BUT THEY ARE THERE’. REPORT FROM THE GYNOCARE TRAINING SCHOOL IN SOFIA, BULGARIA (29TH JUNE-1ST JULY 2023)","authors":"J. Calleja Agius, M. Vasileva Slaveva","doi":"10.48286/aro.2023.73","DOIUrl":"https://doi.org/10.48286/aro.2023.73","url":null,"abstract":"1 Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta 2 Department of Breast Surgery, Dr. Shterev Hospital, Sofia, Bulgaria 3 Research Institute, Medical University Pleven, Pleven, Bulgaria 4 Bulgarian Breast and Gynecological Cancer Association, Sofia, Bulgaria * Correspondence to: jean.calleja-agius@um.edu.mt, https://orcid.org/0000-0001-6369-0297. Jean Calleja-Agius 1, *, Mariela Vasileva-Slaveva 2, 3, 4 ‘THEY ARE RARE, BUT THEY ARE THERE’. REPORT FROM THE GYNOCARE TRAINING SCHOOL IN SOFIA, BULGARIA (29TH JUNE-1ST JULY 2023) Annals of Research in Oncology Vol. 3(3), 132-134, 2023","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Eugeni, B. Giordani, M. Cuomo, G. Duranti, E. Guglielmi, G. Baglio
: In Italy, COVID-19 had a strong impact on health care, quite evident for urgent hospitalization but more marked for scheduled admissions. The aim of this study was to better understand the changes occurred in cancer care during the pandemic period (2020-2021) compared to the previous five years (2015-2019), in terms of differences in volumes, processes and outcomes, especially for breast cancer, for which screening is available, and lung cancer that instead does not benefit from any secondary prevention activity. The study was conducted using data from the National Outcomes Evaluation Program (PNE), which analyses the hospital discharge records provided annually by more than 1,300 public and private Italian hospitals. The findings show that in 2020 a marked reduction was observed in the number of all oncological interventions. In particular, for breast cancer surgery there was a decrease in 2020 of about 6,300 interventions (-10%) compared to 2019. With reference to the number of interventions per month of activity, the negative peak was observed in June 2020. Regarding surgical interventions for lung cancer, in 2020 there were about 1,000 interventions less than in 2019 (-8.6%). The negative peak observed in April 2020 was anticipated compared to breast cancer: in this case, there was no lagged effect on new diagnoses due to the suspension of screening programs. In 2021, there was a resumption of interventions that especially for the breast cancer led to a realignment to the pre-pandemic trend. Our analysis has allowed to appreciate the resilience of the Italian hospital system to the pandemic emergency. However, it will take years to fully assess the impact of delayed or non-performed interventions on the worsening of clinical conditions, especially for the oncological diseases, as well as on the mortality indirectly attributable to COVID-19.
{"title":"Surgical Oncology before and during COVID-19 pandemic: an assessment through the data of the National Outcomes Evaluation Program - PNE","authors":"E. Eugeni, B. Giordani, M. Cuomo, G. Duranti, E. Guglielmi, G. Baglio","doi":"10.48286/aro.2023.75","DOIUrl":"https://doi.org/10.48286/aro.2023.75","url":null,"abstract":": In Italy, COVID-19 had a strong impact on health care, quite evident for urgent hospitalization but more marked for scheduled admissions. The aim of this study was to better understand the changes occurred in cancer care during the pandemic period (2020-2021) compared to the previous five years (2015-2019), in terms of differences in volumes, processes and outcomes, especially for breast cancer, for which screening is available, and lung cancer that instead does not benefit from any secondary prevention activity. The study was conducted using data from the National Outcomes Evaluation Program (PNE), which analyses the hospital discharge records provided annually by more than 1,300 public and private Italian hospitals. The findings show that in 2020 a marked reduction was observed in the number of all oncological interventions. In particular, for breast cancer surgery there was a decrease in 2020 of about 6,300 interventions (-10%) compared to 2019. With reference to the number of interventions per month of activity, the negative peak was observed in June 2020. Regarding surgical interventions for lung cancer, in 2020 there were about 1,000 interventions less than in 2019 (-8.6%). The negative peak observed in April 2020 was anticipated compared to breast cancer: in this case, there was no lagged effect on new diagnoses due to the suspension of screening programs. In 2021, there was a resumption of interventions that especially for the breast cancer led to a realignment to the pre-pandemic trend. Our analysis has allowed to appreciate the resilience of the Italian hospital system to the pandemic emergency. However, it will take years to fully assess the impact of delayed or non-performed interventions on the worsening of clinical conditions, especially for the oncological diseases, as well as on the mortality indirectly attributable to COVID-19.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: In breast surgery, radical procedures such as mastectomies, previously performed only under general anesthesia, are now performed with a patient sedated by wall blocks. Wall blocks are also called fascial blocks and consist in the injection and propagation of local anesthetic through the fascial district where vascular structures and nerves run along; this allows the spread of anesthetic even far from the injection site. The aim of the study was to point out the importance of the dynamic progression of local anesthesia in the interpectoral fascia. The fascial block was difficult to execute, because the neoformation also infiltrated the fascial plan. In this way, we overcame the obstacle with the needle and observed the progress of the local anesthetic so that we had good anesthetic coverage. This study is limited by the fact that it is only one patient, but the concept of dynamic progression of local anesthetic has already been written by other authors (1).
{"title":"THE DYNAMIC “TSUNAMI‐SIGN” TO REPLACE THE “DOUBLE‐V SIGN” FOR AN EFFECTIVE INTERFASCIAL BLOCK? A CASE OF INTERFASCIAL BLOCK IN BREAST LYMPHOMA","authors":"C. D’Errico, P. Fusco, M. Tedesco, G. Sepolvere","doi":"10.48286/aro.2023.71","DOIUrl":"https://doi.org/10.48286/aro.2023.71","url":null,"abstract":": In breast surgery, radical procedures such as mastectomies, previously performed only under general anesthesia, are now performed with a patient sedated by wall blocks. Wall blocks are also called fascial blocks and consist in the injection and propagation of local anesthetic through the fascial district where vascular structures and nerves run along; this allows the spread of anesthetic even far from the injection site. The aim of the study was to point out the importance of the dynamic progression of local anesthesia in the interpectoral fascia. The fascial block was difficult to execute, because the neoformation also infiltrated the fascial plan. In this way, we overcame the obstacle with the needle and observed the progress of the local anesthetic so that we had good anesthetic coverage. This study is limited by the fact that it is only one patient, but the concept of dynamic progression of local anesthetic has already been written by other authors (1).","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135427912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：